Karmakar Partha, Gaitonde Vishwanath
Department of Radiology, Washington University School of Medicine, St. Louis, MO 63110, USA.
Cambrex High Point, Inc., High Point, NC 27265, USA.
Medicines (Basel). 2019 Jan 31;6(1):21. doi: 10.3390/medicines6010021.
Multiple drug resistance (MDR) for the treatment of bacterial infection has been a significant challenge since the beginning of the 21st century. Many of the small molecule-based antibiotic treatments have failed on numerous occasions due to a surge in MDR, which has claimed millions of lives worldwide. Small particles (SPs) consisting of metal, polymer or carbon nanoparticles (NPs) of different sizes, shapes and forms have shown considerable antibacterial effect over the past two decades. Unlike the classical small-molecule antibiotics, the small particles are less exposed so far to the bacteria to trigger a resistance mechanism, and hence have higher chances of fighting the challenge of the MDR process. Until recently, there has been limited progress of clinical treatments using NPs, despite ample reports of in vitro antibacterial efficacy. In this review, we discuss some recent and unconventional strategies that have explored the antibacterial efficacy of these small particles, alone and in combination with classical small molecules in vivo, and demonstrate possibilities that are favorable for clinical translations in near future.
自21世纪初以来,用于治疗细菌感染的多重耐药性(MDR)一直是一项重大挑战。由于多重耐药性激增,许多基于小分子的抗生素治疗多次失败,这在全球范围内已导致数百万例死亡。在过去二十年中,由不同大小、形状和形式的金属、聚合物或碳纳米颗粒(NP)组成的小颗粒(SP)已显示出相当大的抗菌效果。与传统的小分子抗生素不同,小颗粒迄今为止较少暴露于细菌以触发耐药机制,因此更有机会应对多重耐药过程的挑战。直到最近,尽管有大量关于体外抗菌功效的报道,但使用纳米颗粒的临床治疗进展有限。在这篇综述中,我们讨论了一些最新的非传统策略,这些策略探索了这些小颗粒单独以及与经典小分子联合在体内的抗菌功效,并展示了在不久的将来有利于临床转化的可能性。